Rincon Bio performs JIMT-1 xenograft models to test efficacy of preclinical therapies. Please see below for additional information or to request a quote.
JIMT-1 cells have an amplified HER-2 oncogene. They overexpress HER-2 mRNA and protein, and the levels of HER-1, HER-3, and HER-4 mRNA and protein are similar to the trastuzumab-sensitive cell line SKBR-3. The cell line lacks expression of hormone receptors (estrogen receptors and progesterone receptors) and is phenotypically of epithelial progenitor cell origin. JIMT-1 cells are insensitive to trastuzumab and another HER-2-inhibiting drug, pertuzumab (2C4), in vitro and in xenograft tumors. Ref
Forms tumors in nude mice
Used in xenografts to test the efficacy of novel cancer therapeutics
Rincon Bio Growth Curve
Cell Line: JIMT1
Mouse Strain: NOD.CB17 Prkdc<Scid>NCrHsd from Envigo
Positive Control: Kadcyla
Concentration: 2.5mg/kg, 5mg/kg
Dosing: One dose, tail vein
From implant to stratification: 20 days
Cells Implanted per Animal: 5 million
WHY WORK WITH
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
Most efficacy studies can be initiated within two business days.
We love our clients! We are easy to work with. And we take a personal interest in our clients and their studies.